Aldevron to Host Inaugural Breakthrough Symposium

Biotech industry, researchers to discuss advances in gene therapy and
gene editing Nov. 6-7, 2018 in Fargo


FARGO, N.D.–(BUSINESS WIRE)–#biotech–Aldevron, a leader in advancing biological science through the custom
production of plasmids, proteins and antibodies, announced it will host
the inaugural Breakthrough Symposium, Nov. 6-7, 2018, in Fargo, North
Dakota.

Gene and cell therapy and gene editing have seen tremendous growth and
2017 saw product approvals that will begin the transformation of
medicine and how we treat disease. This two-day event will bring
together biotech industry scientists and product developers, government
researchers, medical professionals and members of the academic community
to share the latest breakthroughs and explore the incredible potential
in the field.

Speakers will present a wide array of topics, including clinical
results, novel approaches to gene delivery and modification, and the
latest manufacturing advances. The symposium will spur discussion and
inspire attendees to continue pursuing biotechnology breakthroughs that
improve the lives of people around the world.

Tom Whitehead, co-founder of the Emily Whitehead Foundation, is a
keynote speaker and will share his family’s inspiring firsthand
knowledge of the impact of biotechnology through his daughter Emily’s
cancer treatment. Emily is a three-time cancer survivor and was the
first child in the world to receive the CAR-T cell therapy treatment
that is now an approved product, Kymriah, sold by Novartis.

The theme of this year’s event – Taking Biotech as Far as It Can Go –
recognizes the collaboration necessary to achieve the scientific
breakthroughs vital to industry advancement. It also embraces the
event’s unique location – Fargo, North Dakota, which is home to
Aldevron’s headquarters and new production facility. Event attendees
will have the opportunity to tour the facility as part of the event.

Submissions for the symposium’s poster session are currently being
accepted. Abstract guidelines are available at www.breakthroughsymposium.com/posters.
Potential speakers and/or sponsors are encouraged to contact James Brown
at james.brown@aldevron.com,
or 701.499.7330.

For more information about the Breakthrough Symposium, including agenda
details, submission guidelines and registration information, visit www.breakthroughsymposium.com.

About Aldevron

Aldevron serves the biotechnology industry with custom production of
nucleic acids, proteins, and antibodies. Thousands of clients use
Aldevron-produced plasmids, RNA and gene editing enzymes for projects
ranging from discovery research to clinical trials to commercial
applications. These products are critical raw materials and key
components in commercially available drugs and medical devices. Aldevron
specializes in GMP manufacturing and is known for inventing the
GMP-SourceTM quality system. Company headquarters are in
Fargo, North Dakota, with additional facilities in Madison, Wisconsin,
and Freiburg, Germany. For more information please visit www.aldevron.com.

Contacts

Flint Group for Aldevron
Kris Bevill, 701-499-2180
Kris.bevill@flint-group.com